Isoform-selective anti-TGFβ antibodies and methods of use
US11919948B2 · kind B2 · utility
0Cited by
8References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 18, 2021 |
| Grant date | Mar 5, 2024 |
| Priority date | — |
| Expiry date | Apr 7, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/495
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.